Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. The FDA is revisiting its stance on compounded peptides with plans for advisory panel meetings. Also, a sweeping Cochrane review is fueling fresh debate over amyloid-targeting Alzheimer’s drugs. And more. The need-to-know this morning - Roche said it will run another trial of...